$EGRX
EAGLE PHARMACEUTICALS, INC.

2019 Q4 Form 10-Q Financial Statement

#000082787119000026 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $48.26M $41.15M $56.05M
YoY Change -13.91% -19.85% 19.81%
Cost Of Revenue $11.59M $12.14M $18.56M
YoY Change -37.55% 40.78% 35.38%
Gross Profit $36.67M $26.23M $37.50M
YoY Change -2.21% -31.61% 13.35%
Gross Profit Margin 75.98% 63.73% 66.89%
Selling, General & Admin $22.46M $18.54M $15.48M
YoY Change 45.09% 33.57% 16.22%
% of Gross Profit 61.25% 70.68% 41.29%
Research & Development $11.31M $10.17M $5.860M
YoY Change 93.0% 70.24% -37.92%
% of Gross Profit 30.85% 38.79% 15.63%
Depreciation & Amortization $1.280M $241.0K $840.0K
YoY Change 52.38% -71.31% -11.58%
% of Gross Profit 3.49% 0.92% 2.24%
Operating Expenses $33.77M $43.63M $21.33M
YoY Change 58.32% 32.48% -5.74%
Operating Profit $2.897M -$2.484M $15.73M
YoY Change -81.58% -113.5% 50.6%
Interest Expense -$240.0K $628.0K -$500.0K
YoY Change -52.0% -15.48% 0.0%
% of Operating Profit -8.28% -3.18%
Other Income/Expense, Net $700.0K -$58.00K
YoY Change -92.1%
Pretax Income $3.360M -$2.542M $15.23M
YoY Change -77.94% -114.39% 53.22%
Income Tax $2.350M -$152.0K $2.640M
% Of Pretax Income 69.94% 17.33%
Net Earnings $1.010M -$2.390M $12.59M
YoY Change -91.98% -117.02% 38.5%
Net Earnings / Revenue 2.09% -5.81% 22.46%
Basic Earnings Per Share $0.08 -$0.17 $0.86
Diluted Earnings Per Share $0.08 -$0.17 $0.84
COMMON SHARES
Basic Shares Outstanding 13.67M shares 13.67M shares 14.91M shares
Diluted Shares Outstanding 13.67M shares

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.8M $117.2M $78.80M
YoY Change 39.34% 28.51% -31.3%
Cash & Equivalents $109.8M $117.2M $78.79M
Short-Term Investments
Other Short-Term Assets $1.445M $1.278M $134.0K
YoY Change 978.36% -23.52% -76.11%
Inventory $6.566M $7.247M $8.304M
Prepaid Expenses
Receivables $48.00M $44.81M $66.49M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $179.4M $179.8M $163.8M
YoY Change 9.52% -9.09% -13.17%
LONG-TERM ASSETS
Property, Plant & Equipment $2.202M $2.319M $2.397M
YoY Change -8.14% -9.17% -64.85%
Goodwill $39.74M $39.74M $39.74M
YoY Change 0.0% 0.0% 0.0%
Intangibles $15.58M $16.21M $18.10M
YoY Change -13.92% -13.31% -22.38%
Long-Term Investments
YoY Change
Other Assets $3.908M $4.980M $694.0K
YoY Change 463.11% 605.38% 459.68%
Total Long-Term Assets $75.11M $77.25M $74.76M
YoY Change 0.46% 8.78% -8.12%
TOTAL ASSETS
Total Short-Term Assets $179.4M $179.8M $163.8M
Total Long-Term Assets $75.11M $77.25M $74.76M
Total Assets $254.6M $257.0M $238.6M
YoY Change 6.69% -4.37% -11.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.462M $11.23M $9.917M
YoY Change -44.92% 48.89% -17.23%
Accrued Expenses $28.36M $27.13M $23.52M
YoY Change 20.59% 18.63% 52.81%
Deferred Revenue $8.364M $10.40M $5.869M
YoY Change 42.51%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $5.000M $6.250M
YoY Change -20.0% 0.0% 28.21%
Total Short-Term Liabilities $38.82M $42.36M $39.69M
YoY Change -2.17% 19.62% -16.1%
LONG-TERM LIABILITIES
Long-Term Debt $33.56M $35.69M $38.16M
YoY Change -12.05% -9.22% -11.07%
Other Long-Term Liabilities $3.000M $3.227M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $36.56M $38.91M $38.16M
YoY Change -4.19% -1.01% -11.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.82M $42.36M $39.69M
Total Long-Term Liabilities $36.56M $38.91M $38.16M
Total Liabilities $75.38M $81.27M $77.84M
YoY Change -3.16% 8.77% -13.71%
SHAREHOLDERS EQUITY
Retained Earnings $72.50M $71.50M $58.19M
YoY Change 24.6% 56.8% 121.38%
Common Stock $17.00K $17.00K $17.00K
YoY Change 0.0% 6.25% 6.25%
Preferred Stock
YoY Change
Treasury Stock (at cost) $171.9M $168.9M $153.9M
YoY Change 11.67% 63.31% 90.48%
Treasury Stock Shares 2.908M shares 2.855M shares 2.590M shares
Shareholders Equity $179.2M $175.8M $160.8M
YoY Change
Total Liabilities & Shareholders Equity $254.6M $257.0M $238.6M
YoY Change 6.69% -4.37% -11.65%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income $1.010M -$2.390M $12.59M
YoY Change -91.98% -117.02% 38.5%
Depreciation, Depletion And Amortization $1.280M $241.0K $840.0K
YoY Change 52.38% -71.31% -11.58%
Cash From Operating Activities -$3.200M $10.62M $38.10M
YoY Change -108.4% 187.8% 46.99%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K -$310.0K -$80.00K
YoY Change 62.5% 933.33% -97.07%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$130.0K -$310.0K -$80.00K
YoY Change 62.5% 933.33% -97.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.110M -1.230M -50.46M
YoY Change -91.85% -90.3% 729.93%
NET CHANGE
Cash From Operating Activities -3.200M 10.62M 38.10M
Cash From Investing Activities -130.0K -310.0K -80.00K
Cash From Financing Activities -4.110M -1.230M -50.46M
Net Change In Cash -7.440M 9.080M -12.44M
YoY Change -40.19% -200.67% -172.71%
FREE CASH FLOW
Cash From Operating Activities -$3.200M $10.62M $38.10M
Capital Expenditures -$130.0K -$310.0K -$80.00K
Free Cash Flow -$3.070M $10.93M $38.18M
YoY Change -108.04% 193.82% 33.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16504283 shares
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16524848 shares
CY2018Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2019Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0290
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0294
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0184
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0261
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0272
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0230
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0150
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0145
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M5D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M28D
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2590258 shares
CY2019Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
2855316 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07677
dei Entity File Number
EntityFileNumber
001-36306
dei Entity Registrant Name
EntityRegistrantName
Eagle Pharmaceuticals, Inc.
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
42359000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39686000 USD
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3227000 USD
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8179278
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Tice Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 315
dei Entity Address City Or Town
EntityAddressCityOrTown
Woodcliff Lake
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
326-5300
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13671172 shares
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117211000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78791000 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
44812000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
66486000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
7247000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
8304000 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10516000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10263000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
179786000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
163844000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2319000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2397000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16213000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18103000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
39743000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
39743000 USD
CY2019Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13997000 USD
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13822000 USD
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4980000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000 USD
CY2019Q3 us-gaap Assets
Assets
257038000 USD
CY2018Q4 us-gaap Assets
Assets
238603000 USD
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
11232000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9917000 USD
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27127000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23519000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4000000 USD
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6250000 USD
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35687000 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
38155000 USD
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
273153000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
256458000 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
71495000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
58187000 USD
CY2019Q3 us-gaap Treasury Stock Value
TreasuryStockValue
168900000 USD
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
153900000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
175765000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160762000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
257038000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
238603000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41147000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51337000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147634000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157258000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12137000 USD
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8621000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
39866000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29919000 USD
CY2019Q3 us-gaap Royalty Expense
RoyaltyExpense
2785000 USD
CY2018Q3 us-gaap Royalty Expense
RoyaltyExpense
4370000 USD
us-gaap Royalty Expense
RoyaltyExpense
9440000 USD
us-gaap Royalty Expense
RoyaltyExpense
13440000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10172000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5975000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25504000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38560000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18537000 USD
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13878000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53906000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45033000 USD
CY2019Q3 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2018Q3 us-gaap Restructuring Charges
RestructuringCharges
91000 USD
us-gaap Restructuring Charges
RestructuringCharges
0 USD
us-gaap Restructuring Charges
RestructuringCharges
7479000 USD
CY2019Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2018Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2019Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2704000 USD
CY2018Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-763000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
43631000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
32935000 USD
us-gaap Operating Expenses
OperatingExpenses
128716000 USD
us-gaap Operating Expenses
OperatingExpenses
136372000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2484000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
18402000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
18918000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
20886000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
570000 USD
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
1701000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
36000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
628000 USD
CY2018Q3 us-gaap Interest Expense
InterestExpense
743000 USD
us-gaap Interest Expense
InterestExpense
1979000 USD
us-gaap Interest Expense
InterestExpense
2118000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-58000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-734000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-278000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2082000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2542000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
17668000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18640000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18804000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-152000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3628000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5332000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-509000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2390000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
14040000 USD
us-gaap Net Income Loss
NetIncomeLoss
13308000 USD
us-gaap Net Income Loss
NetIncomeLoss
19313000 USD
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.30
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13668091 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15011159 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13791071 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14903945 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13668091 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15483037 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14147658 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15482768 shares
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
172481000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5651000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2390000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
175765000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
185731000 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4472000 USD
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1933000 USD
CY2018Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2018Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
12109000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
194065000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160762000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16815000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
198000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
15000000 USD
us-gaap Net Income Loss
NetIncomeLoss
13308000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
175765000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
179144000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14512000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8601000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4877000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
22628000 USD
us-gaap Net Income Loss
NetIncomeLoss
19313000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
194065000 USD
us-gaap Net Income Loss
NetIncomeLoss
13308000 USD
us-gaap Net Income Loss
NetIncomeLoss
19313000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-175000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
2040000 USD
us-gaap Depreciation
Depreciation
1479000 USD
us-gaap Depreciation
Depreciation
918000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1890000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1916000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
16815000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
14512000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-763000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
282000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
282000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2704000 USD
us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Restructuring Costs
RestructuringCosts
5771000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-21674000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
24640000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1057000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4525000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
253000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
5709000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1315000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4437000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3608000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7476000 USD
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
1813000 USD
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
582000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
59187000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14276000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
647000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
52000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-647000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
78000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8601000 USD
egrx Payments For Employee Options Exercised
PaymentsForEmployeeOptionsExercised
0 USD
egrx Payments For Employee Options Exercised
PaymentsForEmployeeOptionsExercised
4877000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
198000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
egrx Paymentsfor Contingent Consideration
PaymentsforContingentConsideration
0 USD
egrx Paymentsfor Contingent Consideration
PaymentsforContingentConsideration
15001000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3750000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
15000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
22628000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20120000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-37655000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23431000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78791000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38420000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114657000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117211000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91226000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6587000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1887000 USD
us-gaap Interest Paid Net
InterestPaidNet
1787000 USD
us-gaap Interest Paid Net
InterestPaidNet
1540000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1700000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Basis Of Accounting
BasisOfAccounting
Interim Condensed Consolidated Financial Statements<div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2018 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </span><span style="font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on February 28, 2019. Unless otherwise indicated or required by context, reference throughout to the "Company," "Eagle Pharmaceuticals," "Eagle," "we," "us" or "our" mean Eagle Pharmaceuticals, Inc., a Delaware corporation and its subsidiary, Eagle Biologics, Inc., and references to "Eagle Biologics" mean Eagle Biologics, Inc.</span></div>
CY2019Q3 egrx Number Of Products
NumberOfProducts
2 product
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2855316 shares
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
168900000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation. None of the reclassifications were significant.</span></div>
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14903945 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2018Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
471878 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
356587 shares
CY2019Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
556000 USD
CY2018Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
609000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1673000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2622000 USD
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2476552 shares
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1704348 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2493937 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1810098 shares
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2390000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14040000 USD
us-gaap Net Income Loss
NetIncomeLoss
13308000 USD
us-gaap Net Income Loss
NetIncomeLoss
19313000 USD
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13668091 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15011159 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13791071 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
578823 shares
CY2019Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13668091 shares
CY2018Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15483037 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14147658 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15482768 shares
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.30
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
CY2019Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2164000 USD
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6303000 USD
CY2019Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
4488000 USD
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1776000 USD
CY2019Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
595000 USD
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
225000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
7247000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
8304000 USD
CY2019Q3 us-gaap Prepaid Taxes
PrepaidTaxes
6818000 USD
CY2018Q4 us-gaap Prepaid Taxes
PrepaidTaxes
5739000 USD
CY2019Q3 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1302000 USD
CY2018Q4 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1540000 USD
CY2019Q3 us-gaap Prepaid Insurance
PrepaidInsurance
412000 USD
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
150000 USD
CY2019Q3 egrx Advancestocommercialmanufactures
Advancestocommercialmanufactures
706000 USD
CY2018Q4 egrx Advancestocommercialmanufactures
Advancestocommercialmanufactures
2700000 USD
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1278000 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
134000 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10516000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10263000 USD
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10402000 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5869000 USD
CY2019Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3476000 USD
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7139000 USD
CY2019Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4451000 USD
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5049000 USD
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3617000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2408000 USD
CY2019Q3 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
1757000 USD
CY2018Q4 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
1245000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1084000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2340000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1809000 USD
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27127000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23519000 USD
egrx Number Of Operating Leases
NumberOfOperatingLeases
2 lease
egrx Number Of Operating Leases
NumberOfOperatingLeases
2 lease
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4184000 USD
CY2019Q3 egrx Operating Lease Rightof Use Asset Depreciation
OperatingLeaseRightofUseAssetDepreciation
232000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
286000 USD
egrx Operating Lease Rightof Use Asset Depreciation
OperatingLeaseRightofUseAssetDepreciation
754000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
860000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
860000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
860000 USD
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.06
CY2018 egrx Number Of Operating Leases
NumberOfOperatingLeases
2 lease
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6894000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
287000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1345000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1362000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1376000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1291000 USD
CY2019Q3 egrx Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
820000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
413000 USD
CY2018 egrx Number Of Operating Leases
NumberOfOperatingLeases
2 lease
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3661000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1146000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
864000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
583000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
583000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
485000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23100000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6887000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16213000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
34320000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6278000 USD
CY2018Q4 egrx Finite Lived Intangible Assets Impairment
FiniteLivedIntangibleAssetsImpairment
9939000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18103000 USD
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
630000 USD
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
599000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1890000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1916000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
630000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2666000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2622000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1369000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1570000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
7356000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16213000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
168900000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2786568 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
652625 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
499592 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
391609 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2547992 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2556365 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
600133 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10034 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
20890 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3125574 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4987
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4376
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4376
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5651000 USD
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4472000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16815000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14512000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5651000 USD
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4472000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16815000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14512000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6894000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
287000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1345000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1362000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1376000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1291000 USD
CY2019Q3 egrx Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
820000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
413000 USD
CY2019Q3 us-gaap Long Term Debt
LongTermDebt
40000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
8000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
26000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
0 USD
CY2019Q3 egrx Longterm Debt Maturities Repaymentsof Principalin Year Six
LongtermDebtMaturitiesRepaymentsofPrincipalinYearSix
0 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
0 USD
CY2019Q3 us-gaap Purchase Obligation
PurchaseObligation
24589000 USD
CY2019Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
24589000 USD
CY2019Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2019Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
CY2019Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2019Q3 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0 USD
CY2019Q3 egrx Purchase Obligation Duein Sixth Year
PurchaseObligationDueinSixthYear
0 USD
CY2019Q3 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0 USD
CY2019Q3 egrx Obligations Future Payments
ObligationsFuturePayments
71483000 USD
CY2019Q3 egrx Obligations Future Payments Due Remainder Of Fiscal Year
ObligationsFuturePaymentsDueRemainderOfFiscalYear
25876000 USD
CY2019Q3 egrx Obligations Future Payments Due In Second Year
ObligationsFuturePaymentsDueInSecondYear
6345000 USD
CY2019Q3 egrx Obligations Future Payments Due In Third Year
ObligationsFuturePaymentsDueInThirdYear
9362000 USD
CY2019Q3 egrx Obligations Future Payments Due In Fourth Year
ObligationsFuturePaymentsDueInFourthYear
27376000 USD
CY2019Q3 egrx Obligations Future Payments Due In Fifth Year
ObligationsFuturePaymentsDueInFifthYear
1291000 USD
CY2019Q3 egrx Obligations Future Payments Due In Sixth Year
ObligationsFuturePaymentsDueInSixthYear
820000 USD
CY2019Q3 egrx Obligations Future Payments Due Thereafter
ObligationsFuturePaymentsDueThereafter
413000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
286000 USD
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
135000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
860000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
423000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6894000 USD
CY2019Q3 us-gaap Purchase Obligation
PurchaseObligation
24589000 USD
CY2019Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
407000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
8000000 USD
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
26000000 USD
CY2019Q3 us-gaap Long Term Debt
LongTermDebt
40000000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-152000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3628000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5332000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-509000 USD
CY2018Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.29
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.03
CY2019Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.06
us-gaap Restructuring Charges
RestructuringCharges
7479000 USD
CY2019Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4000000 USD

Files In Submission

Name View Source Status
0000827871-19-000026-index-headers.html Edgar Link pending
0000827871-19-000026-index.html Edgar Link pending
0000827871-19-000026.txt Edgar Link pending
0000827871-19-000026-xbrl.zip Edgar Link pending
asfiledeaglepharma201_image1.gif Edgar Link pending
egrx-20190930.xsd Edgar Link pending
egrx-20190930_cal.xml Edgar Link unprocessable
egrx-20190930_def.xml Edgar Link unprocessable
egrx-20190930_lab.xml Edgar Link unprocessable
egrx-20190930_pre.xml Edgar Link unprocessable
egrxq32019.htm Edgar Link pending
egrxq32019_htm.xml Edgar Link completed
exhibit101revcreditk.htm Edgar Link pending
exhibit311q32019.htm Edgar Link pending
exhibit312q32019.htm Edgar Link pending
exhibit321q32019.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending